Clinical effects of buspirone in social phobia: A double-blind placebo- controlled study

Journal of Clinical Psychiatry

Volumn 58, Issue 4, 1997, Pages 164-168

  Van Vliet, Irene M ^a   Den Boer, Johan A ^a   Westenberg, Herman G M ^a   Ho Pian, Kamini L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BUSPIRONE; CIMETIDINE; CLOMIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; OXAZEPAM; PAROXETINE; SEROTONIN 1A AGONIST; SERTRALINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOCIAL PHOBIA; VERTIGO;

EID: 0030982241     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0405     Document Type: Article

References (43)

1. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992; 49:282-288
2. Amies PL, Gelder MG, Shaw PM. Social phobia: a comparative clinical study. Br J Psychiatry 1983;142:174-179
3. Degonda M, Angst J. The Zurich study: social phobia and agoraphobia. Eur Arch Psychiatry Clin Neurosci 1993;243:95-102
4. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry 1994;151:408-412
5. Heimburg RG, Barlow DH. New developments in cognitive-behavioral therapy for social phobia. J Clin Psychiatry 1991;52(11, suppl):21-30
6. Solyom C, Solyom L, La Pierre Y, et al. Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 1981;16:239-247
7. Liebowitz MR, Gorman JM, Fyer AJ, et al. Social phobia. Arch Gen Psychiatry 1985;42:729-736
8. Versiani M, Mundin FD, Wardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283
9. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992; 2:21-29
10. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase - A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1994;92:351-358
11. Versiani M, Nardi AE, Mindim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360
12. Beaumont G. A large open multicentre trial of clomipramine in the management of phobic disorders. J Int Med Res 1977;5:116-123
13. Gungras M. An uncontrolled trial of clomipramine in the treatment of phobic and obsessional states in general practice. J Int Med Psychol 1977; 32:50-55
14. Pecknold JC, McClure DJ, Appeltauer L, et al. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobia patients? Br J Psychiatry 1982;140:484-490
15. Allsopp L, Cooper G, Polle P. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 1984;9:64-70
16. Sternbach H. Fluoxetine treatment of social phobia [letter]. J Clin Psychopharmacol 1990;10:230
17. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992;4:293-295
18. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32
19. Lepola U, Koponen H, Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry 1994;27:186-188
20. Ringold AL. Paroxetine efficacy in social phobia [letter]. J Clin Psychiatry 1994;55:363-364
21. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141-145
22. Munjack DJ, Flowers C. Sertraline in the treatment of social phobia. Poster presented at the 1994 annual meeting of the American Psychiatric Association; May 22-26, 1994; Philadelphia, Pa
23. van Vliet IM, den Boer JA, Westenberg HGM. A novel psychopharmacological approach to social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115:128-134
24. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371
25. Westenberg HGM, den Boer JA. The neuropharmacology of anxiety. In: den Boer JA, Sitsen JMA, eds. Handbook of Depression and Anxiety: A Biological Approach. New York, NY: Marcel Dekker; 1994:405-446
26. Tunnicliff G, Brokaw JJ, Hausz JA. Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. Neuropharmacology 1992;31:991-995
27. Wheatley D. Buspirone: multicenter efficacy study. J Clin Psychiatry 1982;43(12, sec 2):92-94
28. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry 1989;154:529-534
29. Pecknold JC, Matas M, Howart BG, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam vs placebo. Can J Psychiatry 1989;34:766-771
30. Conn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin 1989;11:304-320
31. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacol 1991;105:428-432
32. Munjack DJ, Bruns J, Baltazar PL, et al. A pilot study of buspirone in the treatment of social phobia. Journal of Anxiety Disorders 1991;87-98
33. Schneier F, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251-256
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
35. Hamilton M. Development for a rating scale for primary depressive illness. Br J Clin Psychol 1967;6:50-55
36. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22: 141-173.
37. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
38. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale: preliminary report. Psychopharmacol Bull 1973;9:13-28
39. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(suppl):67S-76S
40. Heller AH, Beneke M, Spencer D. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 1990;26:58-61
41. Rickels K, Amsterdam JD, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-38
42. Charney DS, Heninger GR, Redmond DE. Yohimbine induced and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983;33:19-29
43. Cowley DS, Hyde TS, Dager SR, et al. Lactate infusion: the role of baseline anxiety. Psychiatry Res 1987;21:169-179